Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shin Nippon Biomedical Laboratories, Ltd. reported better-than-expected financial results for the first half of 2024, driven by strong performance in its domestic nonclinical CRO business and lower-than-expected expenses related to an NDA resubmission. The company’s revenue and profits significantly surpassed forecasts, with interim profit showing a remarkable 55.1% increase over projections.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.